Oruka Therapeutics to report Week 16 data for ORKA-001 psoriasis trial on Oct 26 with live webcast.

Oruka Therapeutics will announce Week 16 results for ORKA-001 from its EVERLAST-B Phase 2b trial targeting moderate-to-severe plaque psoriasis on October 26, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the data. This update is important as ORKA-001 aims to offer a new biologic treatment with infrequent dosing for chronic skin diseases. Investors and interested parties can access the live webcast via Oruka's website, with a replay available afterward.

As of Oct 25, 2026 23:11 WIB, Oruka Therapeutics Inc. common stock (ticker ORKA) is trading at USD 80.15 on Pluang, down 1.23% in the past day. The company has a market capitalization of $5.31 billion and an enterprise value of $4.44 billion. This trading data provides context for the upcoming Week 16 results announcement from the EVERLAST-B trial scheduled for October 26, 2026.